History

The Story Management Has Been Telling

Between the start of 2024 and the start of 2026, Molina's story changed from "the disciplined Medicaid compounder that just keeps executing" to "we are mispricing medical cost trend and need to rebuild the earnings base from scratch." 2024 EPS guidance of $23.50 was largely delivered ($20.42 actual). 2025 guidance of $24.50 was cut twice mid-year and landed at $11.03. 2026 guidance is just $5, a level the company last produced in 2016 — and a securities-fraud class action now covers the period February through July 2025 during which management kept reaffirming the prior story. Credibility has deteriorated sharply; the underlying franchise, by management's own characterization, has not.

1. The Narrative Arc

Anchor years for every other tab. The current CEO took the job in November 2017, in the wake of a -$9.07 EPS year — meaning he inherited a broken business, not a clean compounder. The current strategic chapter — Medicaid-pure-play, RFP discipline plus tuck-in M&A — runs continuously from late 2017, with an acquisition acceleration after the 2020 Magellan deal. Anything you read about "20% revenue CAGR" or "ROE restoration" credits this team; the 2025 collapse also belongs to it, since the same playbook is what was overrun.

2. What Management Emphasized — and Then Stopped Emphasizing

Three things stand out in the heat map. First, "risk corridors" went from being the comforting offset for every miss in 2024 to unmentioned by Q4 2025 — management quietly conceded they had drained the buffer rather than continue framing it as protection. Second, "Marketplace as growth product" was a featured story in 2024, then collapsed into a damage-control narrative by mid-2025 once the segment swung from a projected $3+ EPS contribution to a $2 loss. Third, the "$52B by 2027" headline was reaffirmed even on the Q2 2025 cut call, but went silent by Q4 — replaced by a 2026 revenue number that is actually slightly lower than 2025.

The duals/D-SNP story is the one consistent emphasis through the whole period and continues to grow — partly genuine strategic priority, partly the only growth narrative still standing after the Marketplace and MAPD exits.

3. Risk Evolution

The new risks landscape in the FY2025 10-K. Rate adequacy is now the lead risk — phrased explicitly as "we have seen in prior quarters that medical expenses have risen higher than anticipated, and that our capitation rates have not kept pace." Marketplace volatility, previously a standard disclosure, is now flagged at the same severity, and management quantifies sensitivity bluntly: "if our overall medical care ratio of 91.7% for 2025 had been one percentage point higher, our net income per diluted share would have been approximately $2.72 rather than our actual $8.92, a difference of $6.20." That sensitivity disclosure did not appear at this prominence in 2021.

Risks that quietly dropped out: COVID-19 (top risk in FY2021, gone), the Kentucky Passport litigation (resolved), Magellan transition-services dependence. Newly elevated: OBBBA work requirements (15–20% expected hit on the 1.3M Medicaid Expansion population in 2027–28), embedded-earnings realization (the language now openly admits these may not materialize), and AI / GenAI cybersecurity risk.

4. How They Handled Bad News

The 2024 → 2025 pattern is repetitive and worth seeing in one place: each quarter, management absorbed a small piece of new pressure, called it transient, pointed to a known offset, and reaffirmed the headline number. That continued for five consecutive quarters before the dam broke in Q2 2025.

Pattern of explanations, in order. Q2 2024 was the California retroactive rate hit ("highly unusual for a state to retroactively reduce rates"). Q3 2024 was a second California retroactive cut, plus higher LTSS, pharmacy, behavioral. Q4 2024: corridor protection "didn't pan out." Q1 2025: marketplace prior-year items "non-recurring." Q2 2025: marketplace acuity worse than expected. Q3 2025: half the miss attributed to a segment that is only 10% of revenue. Q4 2025: a third round of California retroactive items.

By Q4 2025 management's own framing had evolved from "transient" and "in line with expectations" to a more honest "trough" and "underfunded by 300–400 basis points." The pivot reads as overdue rather than dishonest — but it is what gives the Hindlemann securities class action (filed Oct 2025, class period Feb 5–Jul 23, 2025) its basic premise: that the rate–trend dislocation was knowable in Q1 while management was reaffirming $24.50.

5. Guidance Track Record

Credibility score: 4/10. Two things hold the score above a 2 or 3. First, the operational promises — RFP wins, M&A execution, expense discipline — were generally kept and represent real franchise value; the $6B Florida CMS Children's contract awarded sole-source in November 2025 is non-trivial. Second, the company stopped reaffirming once the data turned in Q2 2025, rather than dragging the reset across multiple cycles like some peers.

What pulled the score down: management reaffirmed the $24.50 number all the way through April 2025, when (per the Hindlemann complaint) the dislocation between rates and trend was already evident; specific acquisition-accretion promises (Bright +$1 EPS, ConnectiCare +$1 EPS) were not just missed but inverted into headwinds; and the "$4–$5–$5.75–$7.75–$8.65–$11" embedded-earnings ladder grew throughout 2024–25 without any meaningful realization, suggesting the number functioned more as marketing than as a forecast.

6. What the Story Is Now

What has been de-risked. The Marketplace book is being cut by ~50% (≈$2.3B of revenue and ~$5 of historical EPS volatility removed); the MAPD product is exiting for 2027 (~$1 of 2026 drag goes away); RBC ratios at 305% give some balance-sheet runway even after $1B of 2025 buybacks at much higher prices ($297 and $175 avg cost vs. current). The $6B Florida CMS sole-source contract, the Texas STAR/CHIP win, and the duals integration push are real future revenue.

What still looks stretched. (1) The 2026 $5 EPS guide already assumes Medicaid rates roughly match trend (no MCR improvement) — the upside math management offers ($4.50/share per 100bps of MCR) requires states to over-fund by 300–400bps, which hasn't happened in any year of this cycle yet. (2) Debt-to-EBITDA jumped from 1.4x at the start of 2024 to 6.1x at Q1 2026 and the bank syndicate had to amend covenants — leverage is now a constraint, not a tailwind. (3) The Hindlemann class action overhangs the 2025 disclosure record and could affect management bandwidth and reputation through 2026–27. (4) Embedded earnings >$11/share would more than double current earnings power if realized — but the 2024–25 history of those numbers growing without arriving is the obvious warning.

What the reader should believe vs. discount. Believe: the Medicaid franchise is operationally well-run, the team can win RFPs and integrate acquisitions, and the M&A pipeline really does benefit from rivals in worse shape. Discount: the embedded-earnings number until rate cycles show actual catch-up; any reaffirmation language during 2026, given the track record; and the implied "trough" framing — the same team called every quarter of 2024 "transient" before this one. The cycle may turn, but the story has demonstrably been ahead of the cycle.